Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial

INTRODUCTION: Luseogliflozin, a potent, selective sodium glucose cotransporter 2 inhibitor, promotes urinary glucose excretion (UGE) and reduces plasma glucose concentrations. Luseogliflozin was approved for use in Japan after favorable pharmacokinetic, pharmacodynamic, and safety profiles were repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Takashi, Seino, Yutaka, Fukatsu, Atsushi, Ubukata, Michito, Sakai, Soichi, Samukawa, Yoshishige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415995/
https://www.ncbi.nlm.nih.gov/pubmed/25855342
http://dx.doi.org/10.1007/s12325-015-0200-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415995/
https://www.ncbi.nlm.nih.gov/pubmed/25855342
http://dx.doi.org/10.1007/s12325-015-0200-x

Ejemplares similares